Moleculin's Annamycin Shows Strong Cardiac Safety in 90 Patients, Accepted for ASCO Poster
MBRX sits 34% above its 52-week low of $1.79.
Summary
Moleculin Biotech's Annamycin drug candidate showed strong cardiac safety across 90 patients in pooled data, with no evidence of drug-induced cardiotoxicity. This positive data has been accepted for a poster presentation at the ASCO 2026 conference on May 30. This clinical progress is crucial for the company, which has recently issued 'going concern' warnings and engaged in highly dilutive financing activities, including an S-3 filing for the resale of over 100% of outstanding shares. Demonstrating a clean cardiac safety profile for an anthracycline drug like Annamycin addresses a key treatment barrier and supports the ongoing MIRACLE trial, potentially aiding future capital raises.
At the time of this announcement, MBRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $1.79 to $24.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.